References:
1. Yang MH, Wan WQ, Luo JS, Zheng MC, Huang K, Yang LH, et al. Multicenter randomized trial of arsenic trioxide and Realgar-Indigo naturalis formula in pediatric patients with acute promyelocytic leukemia: Interim results of the SCCLG-APL clinical study. Am J Hematol 2018;93(12):1467-1473.
2. Zhu HH, Wu DP, Jin J, Li JY, Ma J, Wang JX, et al. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial. J Clin Oncol 2013;31(33):4215-21.
3. Kutny MA, Alonzo TA, Gerbing RB, Wang YC, Raimondi SC, Hirsch BA, et al. Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children’s Oncology Group Phase III Historically Controlled Trial AAML0631. J Clin Oncol 2017;35(26):3021-3029.
4. Iland HJPC, Group ALAL. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic Leukemia in the Australasian Leukemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial. Lancet Haematol 2015;2(9):e357 - e366.
5. Kayser S, Schlenk RF, Platzbecker U. Management of patients with acute promyelocytic leukemia. Leukemia 2018;32(6):1277-1294.
6. Wang L, Zhou GB, Liu P, Song JH, Liang Y, Yan XJ, et al. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci U S A 2008;105(12):4826-31.
7. Zhu H, Guo Z, Jia J, Jiang Q, Jiang H, Huang X. The impact of oral arsenic and all-trans-retinoic acid on coagulopathy in acute promyelocytic leukemia. Leukemia Research 2018;65:14-19.
8. Wang F, Jia J, Wang J, Zhao T, Jiang Q, Jiang H, et al. The kinetics of white blood cell and the predictive factors of leukocytosis under oral or intravenous arsenic as the first-line treatment for acute promyelocytic leukemia. Leukemia Research 2017;61:84-88.
9. Kutny MA, Gregory J, Feusner JH. Treatment of paediatric APL: How does the therapeutic approach differ from adults? Best Practice & Research Clinical Haematology 2014;27(1):69-78.
10. Creutzig U, Dworzak MN, Bochennek K, Faber J, Flotho C, Graf N, et al. First experience of the AML-Berlin-Frankfurt-Munster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic trioxide and all-trans retinoid acid. Pediatr Blood Cancer 2017;64(8).
11. Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, et al. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. Journal of Clinical Oncology 2017;35(6):605-612.
12. Lo-Coco F AGVM, dell’Adulto GIME, Group GAML, Leukemia SA. Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia. N Engl J Med 2013;369:111-21.
13. Zhang L, Zou Y, Chen Y, Guo Y, Yang W, Chen X, et al. Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial. BMC Cancer 2018;18(1):374.
14. Zhu HH, Huang XJ. Oral arsenic and retinoic acid for non-high-risk acute promyelocytic leukemia. N Engl J Med 2014;371(23):2239-41.
15. Zhu HH, Wu DP, Du X, Zhang X, Liu L, Ma J, et al. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic Leukemia: a non-inferiority, randomised phase 3 trial. Lancet Oncol 2018;19(7):871-879.
16. Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 1997;89(9):3345-53.
17. Abedin S, Altman JK. Acute promyelocytic leukemia: preventing early complications and late toxicities. Hematology Am Soc Hematol Educ Program 2016;2016(1):10-15.
18. Zheng H, Jiang H, Hu S, Liao N, Shen D, Tian X, et al. Arsenic Combined With All-Trans Retinoic Acid for Pediatric Acute Promyelocytic Leukemia: Report From the CCLG-APL2016 Protocol Study. J Clin Oncol 2021:JCO2003096.
19. Tallman MS, Altman JK. How I treat acute promyelocytic leukemia. Blood 2009;114(25):5126-35.
20. Ossenkoppele G, Schuurhuis GJ. MRD in AML: does it already guide therapy decision-making? Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):356-365.
21. Benjamini O, Dumlao TL, Kantarjian H, O’Brien S, Garcia-Manero G, Faderl S, Jorgensen J, Luthra R, Garris R, Thomas D, Kebriaei P, Champlin R, Jabbour E, Burger J, Cortes J, Ravandi F. Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. Am J Hematol. 2014 Mar;89(3):282-7.